Search

Your search keyword '"Millward M"' showing total 755 results

Search Constraints

Start Over You searched for: Author "Millward M" Remove constraint Author: "Millward M"
755 results on '"Millward M"'

Search Results

1. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

2. The SPHERE infrared survey for exoplanets (SHINE)- I Sample definition and target characterization

4. Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma in Patients with Concomitant Chronic Lymphocytic Leukemia

5. SPHERE dynamical and spectroscopic characterization of HD142527B

6. The beta Pictoris association low-mass members: membership assessment, rotation period distribution, and dependence on multiplicity

7. Testing giant planet formation in the transitional disk of SAO 206462 using deep VLT/SPHERE imaging

8. The beta Pictoris association: Catalog of photometric rotational periods of low-mass members and candidate members

9. The rotation - Lithium depletion correlation in the beta Pictoris association and LDB age determination

10. Characterizing HR3549B using SPHERE

11. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

12. First light of the VLT planet finder SPHERE. II. The physical properties and the architecture of the young systems PZ Tel and HD 1160 revisited

14. 44P Exploratory analysis of peripheral pharmacodynamic (PD) biomarkers after sitravatinib (Sitra) and tislelizumab (TIS) in advanced solid tumors: SAFFRON-103

17. OA01.07 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations

18. A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial

19. 76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

23. EP16.03-005 Australian Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Practices - A Survey of Medical Oncologists and Pathologists

24. LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

27. 1197TiP A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

28. EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment

29. 987P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study

33. 623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12

35. Safety/tolerability and preliminary antitumour activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC).

36. Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.

37. A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.

39. Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

40. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

42. The SPHERE infrared survey for exoplanets (SHINE)

43. 153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

46. OA15.02 Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations

48. A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial

Catalog

Books, media, physical & digital resources